Literature DB >> 19875293

TOR complex 2: a signaling pathway of its own.

Nadine Cybulski1, Michael N Hall.   

Abstract

Research on TOR has grown exponentially during the last decade, generating a complex model of the TOR signaling network. Rapamycin treatment provides a simple and straightforward method to inhibit the TOR signaling pathway and to study the influence of TOR on multiple cellular processes. The discovery of two distinct TOR complexes, TORC1 and TORC2, showed that studies using rapamycin targeted only one TOR signaling branch. TORC1 is directly inhibited by rapamycin, whereas TORC2 is not. There is no known TORC2-specific inhibitor, so genetic manipulation is required to study its biological function(s). Many studies in genetically tractable model organisms have expanded our understanding of TORC2 signaling. Here we focus on the TORC2 signaling pathway as revealed by these (mostly recent) studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19875293     DOI: 10.1016/j.tibs.2009.09.004

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  133 in total

Review 1.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

Review 2.  Pleiotropic signaling pathways orchestrate yeast development.

Authors:  Joshua A Granek; Ömür Kayıkçı; Paul M Magwene
Journal:  Curr Opin Microbiol       Date:  2011-09-28       Impact factor: 7.934

3.  Antagonistic interactions between the cAMP-dependent protein kinase and Tor signaling pathways modulate cell growth in Saccharomyces cerevisiae.

Authors:  Vidhya Ramachandran; Paul K Herman
Journal:  Genetics       Date:  2010-11-15       Impact factor: 4.562

4.  MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

Authors:  Denghong Zhang; Riccardo Contu; Michael V G Latronico; Jianlin Zhang; Jian Ling Zhang; Roberto Rizzi; Daniele Catalucci; Shigeki Miyamoto; Katherine Huang; Marcello Ceci; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Kun-Liang Guan; Joan Heller Brown; Ju Chen; Nahum Sonenberg; Gianluigi Condorelli
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

5.  Rab-family GTPase regulates TOR complex 2 signaling in fission yeast.

Authors:  Hisashi Tatebe; Susumu Morigasaki; Shinichi Murayama; Cui Tracy Zeng; Kazuhiro Shiozaki
Journal:  Curr Biol       Date:  2010-10-28       Impact factor: 10.834

Review 6.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

7.  Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.

Authors:  Jessica K Altman; Antonella Sassano; Surinder Kaur; Heather Glaser; Barbara Kroczynska; Amanda J Redig; Suzanne Russo; Sharon Barr; Leonidas C Platanias
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

Review 8.  Cell motility in cancer invasion and metastasis: insights from simple model organisms.

Authors:  Christina H Stuelten; Carole A Parent; Denise J Montell
Journal:  Nat Rev Cancer       Date:  2018-03-16       Impact factor: 60.716

9.  Insulin-induced de novo lipid synthesis occurs mainly via mTOR-dependent regulation of proteostasis of SREBP-1c.

Authors:  Qingming Dong; Gipsy Majumdar; Robert N O'Meally; Robert N Cole; Marshall B Elam; Rajendra Raghow
Journal:  Mol Cell Biochem       Date:  2019-09-20       Impact factor: 3.396

10.  The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates.

Authors:  Alexandre Soulard; Alessio Cremonesi; Suzette Moes; Frédéric Schütz; Paul Jenö; Michael N Hall
Journal:  Mol Biol Cell       Date:  2010-08-11       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.